Federal Register / Vol. 66, No. 34 / Tuesday, February 20, 2001 / Notices 10895

Committee Information Line, 1–800–741–

8138 (301–443–0572 in the Washington, DC

area), code 12391. Please call the Information

Line for up-to-date information on this

meeting.

Agenda: On March 7, 2001, the committee

will review safety and immunogenicity data

for a combination vaccine, DTaP—Hepatitis

B–IPV, manufactured by SmithKline

Beecham Biologicals. On March 8, 2001, the

committee will discuss approaches to

develop new pneumococcal conjugate

vaccines for U.S. licensure. On March 9,

2001, the committee will complete

recommendations pertaining to the influenza

virus vaccine formulations for the 2001 to

2002 season and be briefed on research

programs in the Laboratory of Retroviruses

and the Laboratory of Immunoregulation.

Procedure: On March 7, 2001, from 9:15

a.m. to 6:30 p.m., the meeting is open to the

public. On March 8, 2001, from 10 a.m. to

6:30 p.m., the meeting is open to the public.

On March 9, 2001, from 8 a.m. to 11 a.m.,

the meeting is open to the public. Interested

persons may present data, information, or

views, orally or in writing, on issues pending

before the committee. Written submissions

may be made to the contact person by

February 28, 2001. Oral presentations from

the public will be scheduled between

approximately 1:30 p.m. and 2 p.m. on

March 7, 2001. On March 8, 2001, oral

presentations will be held between

approximately 2 p.m. and 2:30 p.m. Time

allotted for each presentation may be limited.

Those desiring to make formal oral

presentations should notify the contact

person before February 28, 2001, and submit

a brief statement of the general nature of the

evidence or arguments they wish to present,

the names and addresses of proposed

participants, and an indication of the

approximate time requested to make their

presentation.

Closed Committee Deliberations: On March

7, 2001, from 8 a.m. to 9 a.m. and on March

8, 2001, from 8 a.m. to 10 a.m., the meeting

will be closed to permit discussion and

review of trade secret and/or confidential

information (5 U.S.C. 552b(c)(4)). This

portion of the meeting will be closed to

permit discussion of pending investigational

new drug applications or pending product

licensing applications. On March 9, 2001,

from 11 a.m. to 12:30 p.m., the meeting will

be closed to permit discussion where

disclosure would constitute a clearly

unwarranted invasion of personal privacy (5

U.S.C. 552b(c)(6)). The meeting will be

closed to discuss personal information

concerning individuals associated with the

research programs.

Notice of this meeting is given under the

Federal Advisory Committee Act (5 U.S.C.

app. 2).

Dated: February 14, 2001.

Bonnie H. Malkin,

Special Assistant to the Senior Associate

Commissioner.

[FR Doc. 01–4142 Filed 2–16–01; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Submission for OMB Review;

Comment Request; Evaluation of

National Youth Anti-Drug Media

Campaign

SUMMARY: Under the provisions of

section 3507(a)(1)(D) of the Paperwork

Reduction Act of 1995, the National

Institute on Drug Abuse, the National

Institutes of Health, has submitted to the

Office of Management and Budget

(OMB) a request to review and approve

the information collection listed below.

This proposed information collection

was previously published in the Federal

Register on October 17, 2000 and

allowed 60 days for public comment. No

public comments were received. The

purpose of this notice is to allow an

additional 30 days for public comment.

Proposed Collection

Title: Evaluation of National Youth

Anti-Drug Media Campaign, OMB No.

0925–0466. Information Collection

Request: Revision. Need and Use of

Information Collection: In 1998, the

White House Office of National Drug

Control Policy transferred funds to

NIDA to conduct an independent,

scientifically designed and

implemented evaluation of the National

Youth Anti-Drug Media Campaign, the

first prevention campaign to use paid

advertising to discourage youth from

drug use. The study is assessing the

outcomes and impact of the national

campaign in reducing illegal drug use

among children and adolescents.

In the first year, two surveys were

conducted: (1) The National Survey of

Parents and Youth (NSPY), a crosssectional household survey; and (2) the

Community Longitudinal Study of

Parents and Youth (CLSPY) in four

communities with an ethnographic

component. The purpose of this revision

is to discontinue the CLSPY and

incorporate its longitudinal component

into the NSPY to maximize resources

and strengthen analytic ability. The

revised NSPY will be the first to

measure the effectiveness of a media

campaign by following a large

nationally-representative cohort of

parents and children from the same

household as they are exposed to a

media campaign over time. All data will

continue to be collected using a

combination of computer-assisted

personal interviews (CAPI) and audio

computer-assisted self-interviews

(ACASI). The findings form the basis of

semiannual and annual reports on

campaign progress. These reports

provide assistance in improving the

national campaign, and will help to

establish a rich data base of information

about the process involved in changing

attitudes and behaviors by the mass

media.

Frequency of Response: The revised

NSPY data collection will continue over

a four-year period, ending in December

2003. Each data collection wave will

last approximately 6 months. Affected

Public: Individuals and households.

Types of Respondents: Children and

parents. The annual reporting burden,

which will drop substantially from the

original design, is as follows:

ESTIMATED RESPONDENT BURDEN WAVES 3 THROUGH 7 (1/1/01 THROUGH 12/31/03)

Type of respondents

Estimated

number of

respondents

Estimated

number of responses per

respondent

Average time

in hours per

response

Estimated total

burden hours

Estimated annual hour burden (over 3

years)

National Survey of Parents and Youth (NSPY)

Baseline (Wave 3):

Screener respondent .................................................... 23,300 1 .07 1,631 544

Youth 9–11 ................................................................... 937 1 .58 543 181

Adolescents 12–18 ....................................................... 1,457 1 .75 1,093 364

Parents .......................................................................... 1,654 1 .92 1,522 507

Followup (Waves 4–7):

Screener respondent .................................................... 4,849 2 .10 970 323

Youth 9–11 ................................................................... 1,315 2 .58 1,525 508

Adolescents 12–18 ....................................................... 5,094 2 .75 7,641 2,547

10896 Federal Register / Vol. 66, No. 34 / Tuesday, February 20, 2001 / Notices

ESTIMATED RESPONDENT BURDEN WAVES 3 THROUGH 7 (1/1/01 THROUGH 12/31/03)—Continued

Type of respondents

Estimated

number of

respondents

Estimated

number of responses per

respondent

Average time

in hours per

response

Estimated total

burden hours

Estimated annual hour burden (over 3

years)

Parents .......................................................................... 4,564 2 .92 8,398 2,799

Total estimated burden .......................................... 43,170 ........................ .54 23,323 7,774

There are no Capital Costs to report.

There are no Operating or Maintenance

Costs to report. Because of the

sensitivity of collecting data from

families in households involving

children as young as 9 years old, and

the importance of minimizing costs for

repetitive, return visits to obtain

respondent cooperation, NIDA provides

a reasonable cost incentive to reimburse

respondents for their time, as approved

by OMB.

Request for Comments

Written comments and/or suggestions

from the public and affected agencies

are invited on one or more of the

following points: (1) Whether the

proposed revision in the data collection

is necessary for the proper performance

of the function of the agency, including

whether the information will have

practical utility; (2) the accuracy of the

agency’s estimate of the burden of the

proposed revision, including the

validity of the methodology and

assumptions used; (3) ways to enhance

the quality, utility, and clarity of the

information to be collected; and (4)

ways to minimize the burden of the

collection of information on those who

are to respond, including the use of

appropriate automated, electronic,

mechanical, or other technological

collection techniques or other forms of

information technology.

Direct Comments To OMB

Written comments and/or suggestions

regarding the items(s) contained in this

notice, especially regarding the

estimated public burden and associated

response time, should be directed to the:

Office of Management and Budget,

Office of Regulatory Affairs, New

Executive Office Building, Room 10235,

Washington, DC 20503. Attention: Desk

Officer for NIH. To request more

information on the proposed project or

to obtain a copy of the data collection

plans and instruments, contact Susan L.

David, Project Officer; Division of

Epidemiology, Services, and Prevention

Research, National Institute on Drug

Abuse, 6001 Executive Blvd. Room

5153, MSC 9589, Bethesda, MD 20892–

9589; or call non-toll-free number (301)

443–6504; or fax to (301) 443–2636; or

email your request, including your

address, to: sdavid@nida.nih.gov.

Comments Due Date

Comments regarding this information

collection are best assured of having

their full effect if received on or before

March 22, 2001.

Dated: February 12, 2001.

Laura Rosenthal,

Executive Officer, NIDA.

[FR Doc. 01–4092 Filed 2–16–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Meeting

Pursuant to section 10(a) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of a meeting of the

National Cancer Institute Director’s

Consumer Liaison Group.

The meeting will be open to the

public, with attendance limited to space

available. Individuals who plan to

attend and need special assistance, such

as sign language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

Name of Committee: National Cancer

Institute Director’s Consumer Liaison Group.

Date: March 6, 2001.

Time: 12:30 p.m. to 2:30 p.m.

Agenda: To get updates from the working

groups and to discuss the advocates section

of the April 2001 DCLG meeting.

Place: National Cancer Institute, 6116

Executive Boulevard, Suite 300 C, Rockville,

MD 20852, (Telephone Conference Call).

Contact Person: Elaine Lee, Acting

Executive Secretary, Office of Liaison

Activities, National Institutes of Health,

National Cancer Institute, 6116 Executive

Boulevard, Suite 300 C, Bethesda, MD 20892,

301/594–3194.

Information is also available on the

Institute’s/Center’s home page:

deainfo.nci.nih.gov/advisory/dclg/delg.htm,

where an agenda and any additional

information for the meeting will be posted

when available.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: February 9, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–4090 Filed 2–16–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse;

Notice of Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute on

Drug Abuse Special Emphasis Panel,

Minority Institutions’ Drug Abuse Research

Development Program.

Date: March 23, 2001.

Time: 2 p.m. to 3 p.m.

Agenda: To review and evaluate grant

applications.

Place: Neuroscience Center, National

Institutes of Health, 6001 Executive Blvd.,

Bethesda, MD 20892, (Telephone Conference

Call).

Contact Person: Marina L. Volkov, PhD,

Health Scientist Administrator, Office of

Extramural Program Review, National

Institute on Drug Abuse, National Institutes